Contents

Search

strontium-89 chloride (Metastron)

Indications: - used in the treatment of painful bony metastases - preferentially targets metabolically active regions of bone Dosage: - intravenous: - 10.9-22.6 mg, Water for Injection q.s. to 1 mL - 1 mCi/mL - a repeat dose can be administered at 3-month intervals if necessary Pharmacokinetics: - bone pain relief is generally seen within 7-21 days & sustained for 3-6 months

General

strontium chloride radiopharmaceutical

References

  1. Strontium-89 chloride http://www.cancer.org/treatment/treatmentsandsideeffects/guidetocancerdrugs/strontium-89-chloride
  2. MedlinePlus: Strontium-89 Chloride http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601004.html
  3. RxList: Metastron http://www.rxlist.com/metastron-drug.htm

Components

strontium-89